Recent evidence indicated that CRC could be further classified into five prespecified subtypes using a biomarker combination of KRAS and BRAFV600E mutations, MMR status and MLH1 methylation with statistically significant differences in clinicopathologic features and patient survival rates [29]. This evidence concerns the gene MRC1 and colorectal carcinoma.